SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration

Li,Shihao; Li,Zihao; Huang,Lan; Geng,Zhenyang; Li,Feng; Wu,Bin; Sheng,Yinliang; Xu,Yifan; Li,Bowen; Xu,Yiming; Gu,Zhuoyu; Qi,Yu

doi:10.3892/ijo.2024.5618

SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration

Authors:
- Shihao Li
- Zihao Li
- Lan Huang
- Zhenyang Geng
- Feng Li
- Bin Wu
- Yinliang Sheng
- Yifan Xu
- Bowen Li
- Yiming Xu
- Zhuoyu Gu
- Yu Qi
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China, Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China
Published online on: January 23, 2024 https://doi.org/10.3892/ijo.2024.5618
Article Number: 30
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Solute carrier organic anion transporter family member 4A1 (SLCO4A1) is a membrane transporter protein. The role of this molecule in non‑small cell lung cancer (NSCLC) remains unclear. Bulk sequencing was carried out using early‑stage NSCLC tissues with lymph node metastasis to identify SLCO4A1 that influences NSCLC cell proliferation, metastasis and prognosis. The in vitro functional assays carried out included the following: Cell Counting Kit‑8, plate colony formation, Transwell and wound healing assays. The molecular techniques used included reverse transcription‑quantitative PCR, western blotting and immunohistochemistry. The present study revealed the role of SLCO4A in NSCLC. SLCO4A1 was found to be expressed at high levels in NSCLC tissues and cells, and promotes cell proliferation, migration and invasion. Kaplan‑Meier survival analysis indicated that patients with NSCLC and high expression of SLCO4A1 had a poor prognosis. SLCO4A was revealed to regulate the expression of the proliferation‑related proteins Ki‑67 and PCNA, and that of the extracellular matrix proteins vimentin and E‑cadherin. Mechanistically, SLCO4A1 may affect the MAPK signaling pathway to promote NSCLC cell proliferation, migration and invasion. In addition, bioinformatics analysis demonstrated a strong association between SLCO4A1 and tumor infiltrating immune cells, highlighting its critical role in immune therapies such as immune checkpoint inhibitor treatment of patients with NSCLC.

View Figures

View References

1	Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ, Estève J, et al: Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 391:1023–1075. 2018.
2	Sher T, Dy GK and Adjei AA: Small cell lung cancer. Mayo Clin Proc. 83:355–367. 2008.
3	Noguchi M, Morikawa A, Kawasaki M, Matsuno Y, Yamada T, Hirohashi S, Kondo H and Shimosato Y: Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 75:2844–2852. 1995.
4	Xu W, Chen B, Ke D and Chen X: TRIM29 mediates lung squamous cell carcinoma cell metastasis by regulating autophagic degradation of E-cadherin. Aging (Albany NY). 12:13488–13501. 2020.
5	Caiola E, Iezzi A, Tomanelli M, Bonaldi E, Scagliotti A, Colombo M, Guffanti F, Micotti E, Garassino MC, Minoli L, et al: LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. J Thorac Oncol. 15:360–370. 2020.
6	Dong B, Wu C, Huang L and Qi Y: Macrophage-Related SPP1 as a potential biomarker for early lymph node metastasis in lung adenocarcinoma. Front Cell Dev Biol. 9:7393582021.
7	Martinez-Zayas G, Almeida FA, Yarmus L, Steinfort D, Lazarus DR, Simoff MJ, Saettele T, Murgu S, Dammad T, Duong DK, et al: Predicting lymph node metastasis in non-small cell lung cancer: Prospective external and temporal validation of the HAL and HOMER Models. Chest. 160:1108–1120. 2021.
8	Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M and Tsuji A: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun. 273:251–260. 2000.
9	Leuthold S, Hagenbuch B, Mohebbi N, Wagner CA, Meier PJ and Stieger B: Mechanisms of pH-gradient driven transport mediated by organic anion polypeptide transporters. Am J Physiol Cell Physiol. 296:C570–C582. 2009.
10	Hagenbuch B and Meier PJ: Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447:653–665. 2004.
11	Brenner S, Klameth L, Riha J, Schölm M, Hamilton G, Bajna E, Ausch C, Reiner A, Jäger W, Thalhammer T and Buxhofer-Ausch V: Specific expression of OATPs in primary small cell lung cancer (SCLC) cells as novel biomarkers for diagnosis and therapy. Cancer Lett. 356(2 Pt B): 517–524. 2015.
12	Chen X, Yi G, Zhou Y, Hu W, Xi L, Han W and Wang F: Prognostic biomarker SLCO4A1 is correlated with tumor immune infiltration in colon adenocarcinoma. Mediators Inflamm. 2023:49264742023.
13	Hays A, Apte U and Hagenbuch B: Organic anion transporting polypeptides expressed in pancreatic cancer may serve as potential diagnostic markers and therapeutic targets for early stage adenocarcinomas. Pharm Res. 30:2260–2269. 2013.
14	Benito-Martin A and Peinado H: FunRich proteomics software analysis, let the fun begin! Proteomics. 15:2555–2556. 2015.
15	Ellis K, Kerr J, Godbole S, Lanckriet G, Wing D and Marshall S: A random forest classifier for the prediction of energy expenditure and type of physical activity from wrist and hip accelerometers. Physiol Meas. 35:2191–2203. 2014.
16	Kang J, Choi YJ, Kim IK, Lee HS, Kim H, Baik SH, Kim NK and Lee KY: LASSO-Based machine learning algorithm for prediction of lymph node metastasis in T1 Colorectal Cancer. Cancer Res Treat. 53:773–783. 2021.
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
18	Horvath L, Thienpont B, Zhao L, Wolf D and Pircher A: Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)-novel approaches and future outlook. Mol Cancer. 19:1412020.
19	Liu WJ, Du Y, Wen R, Yang M and Xu J: Drug resistance to targeted therapeutic strategies in non-small cell lung cancer. Pharmacol Ther. 206:1074382020.
20	Lee EY and Muller WJ: Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol. 2:a0032362010.
21	Stella GM, Luisetti M, Pozzi E and Comoglio PM: Oncogenes in non-small-cell lung cancer: Emerging connections and novel therapeutic dynamics. Lancet Respir Med. 1:251–261. 2013.
22	Thomas A, Liu SV, Subramaniam DS and Giaccone G: Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol. 12:511–526. 2015.
23	Cai Z and Liu Q: Understanding the Global Cancer Statistics 2018: Implications for cancer control. Sci China Life Sci. 64:1017–1020. 2021.
24	Barta JA, Powell CA and Wisnivesky JP: Global epidemiology of lung cancer. Ann Glob Health. 85:82019.
25	Bille A, Woo KM, Ahmad U, Rizk NP and Jones DR: Incidence of occult pN2 disease following resection and mediastinal lymph node dissection in clinical stage I lung cancer patients. Eur J Cardiothorac Surg. 51:674–679. 2017.
26	Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A and Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 306:703–708. 2003.
27	König J, Seithel A, Gradhand U and Fromm MF: Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol. 372:432–443. 2006.
28	Wang XS, Wu SL, Peng Z and Zhu HH: SLCO4A1 is a Prognosis-Associated Biomarker Involved in Neutrophil-Mediated Immunity in Thyroid Cancer. Int J Gen Med. 14:9615–9628. 2021.
29	Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL and Mostaghel EA: Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev. 20:619–627. 2011.
30	Buxhofer-Ausch V, Secky L, Wlcek K, Svoboda M, Kounnis V, Briasoulis E, Tzakos AG, Jaeger W and Thalhammer T: Tumor-specific expression of organic anion-transporting polypeptides: Transporters as novel targets for cancer therapy. J Drug Deliv. 2013:8635392013.
31	Stieger B and Hagenbuch B: Organic anion-transporting polypeptides. Curr Top Membr. 73:205–532. 2014.
32	Takada K, Kashiwagi S, Asano Y, Goto W, Kouhashi R, Yabumoto A, Morisaki T, Shibutani M, Takashima T, Fujita H, et al: Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer. BMC Cancer. 20:5982020.